Difference between revisions of "Fluoxetine-clomipramine"

From Psychiatrienet
Jump to: navigation, search
Line 11: Line 11:
 
* '''Day 28:''' gradually increase dosage of clomipramine to 75 mg/day and more.
 
* '''Day 28:''' gradually increase dosage of clomipramine to 75 mg/day and more.
 
| info =   
 
| info =   
* Fluoxetine slows the metabolism of clomipramine via CYP2D6.  
+
* Fluoxetine and norfluoxetine slow the metabolism of clomipramine via CYP2D6.  
* Desmethylfluoxetine has a halflife of at least 1 week: it takes therefore 1 month for elemination.
+
* Norfluoxetine has a halflife of at least 1 week: it takes therefore 1 month for elemination.
 
* Start low, go slow for clomipramine.
 
* Start low, go slow for clomipramine.
 
}}
 
}}

Revision as of 15:15, 27 November 2009

Fluoxetine
Type Antidepressant
Group SSRI
links
Medscape Fluoxetine
PubChem 3386
PubMed Fluoxetine
Kompas (Dutch) Fluoxetine
Wikipedia Fluoxetine
Clomipramine
Type Antidepressant
Group TCA
links
ATC-code N06AA04
Medscape Clomipramine
PubChem 2801
PubMed Clomipramine
Kompas (Dutch) Clomipramine
Wikipedia Clomipramine

Switch medication from fluoxetine to clomipramine.[1] [2]

Nietinrijdenbord.png Stop fluoxetine
  • Gradually reduce dosage of fluoxetine to a maximum of 20 mg/ day, when this dosage is > 20 mg/day.
  • When a dosage of 20 mg/day is reached, stop administration.
Eenrichtingbord.png Start clomipramine

Caution is necessary for at least four weeks.

  • Day 1: start administration of clomipramine in a low dosage of 25 mg/day.
  • Day 8: increase dosage of clomipramine to 50 mg/day.
  • Day 28: gradually increase dosage of clomipramine to 75 mg/day and more.
Infobord.png More information
  • Fluoxetine and norfluoxetine slow the metabolism of clomipramine via CYP2D6.
  • Norfluoxetine has a halflife of at least 1 week: it takes therefore 1 month for elemination.
  • Start low, go slow for clomipramine.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.